ASX Announcement CLEO Screening Test Meets Rigorous Performance Targets in First Proof-of- Concept Study Highlights • Prototype Screening Test has met and exceeded its pre-de?ned performance thresholds in its ?rst proof-of-concept study of 247 individuals • In a cohort enriched with 62 Stage I...
CLEO Screening Test Meets Rigorous Performance Targets
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Cleo Diagnostics Ltd has announced that its prototype ovarian cancer screening test has successfully met and exceeded performance targets in its first proof-of-concept study involving a cohort of individuals. The study demonstrated high sensitivity and specificity for both high-risk and general populations, particularly for early-stage cancers, which are crucial for improving survival rates. Cleo plans to advance its screening development program with further studies to confirm these initial results and assess the test's performance in broader populations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from CLEO Diagnostics
- CLEO Commences Analytical Validation Ahead of FDA Submission
- Cleo Files Patents for its Ovarian Cancer Screening Test
- CLEO Commences Ovarian Cancer Screening Test Development
- Letter to Shareholders
- Notice of Annual General Meeting/Proxy Form
Later from CLEO Diagnostics
All CLEO Diagnostics news releasesFollow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics